Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia

Journal of Clinical Pharmacology

Volumn 40, Issue 4, 2000, Pages 421-429

  Raungaard, Bent ^a   Brorholt Petersen, Jens Uffe ^a   Jensen, Henrik Kjærulf ^a   Færgeman, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; CELL STIMULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAMILIAL DISEASE; FLOW CYTOMETRY; HETEROZYGOTE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIVER CELL; LYMPHOCYTE ACTIVATION; RECEPTOR INTRINSIC ACTIVITY;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARBOCYANINES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; FATTY ACIDS, MONOUNSATURATED; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INDOLES; LIPOPROTEINS, LDL; MUTATION; PROTEIN BINDING; RECEPTORS, LDL; T-LYMPHOCYTES; TRIGLYCERIDES;

EID: 0033638419     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009008     Document Type: Article

References (56)

1. Screening for hyperlipoproteinemia in 10,000 Danish newborns: Follow-up studies in 522 children with elevated cord serum VLDL-LDL-cholesterol
2. Familial hypercholesterolemia
3. Metabolic studies in familial hypercholesterolemia: Evidence for a gene-dosage effect in vivo
4. The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits
8. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol
9. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: Increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor: Results from a novel triple-tracer approach
10. Lipoprotein receptors in the liver: Control signals for plasma cholesterol traffic
11. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation
12. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins
13. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: Pathophysiological and therapeutic implications
14. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors
15. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia
16. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia
17. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: Atorvastatin versus lovastatin
18. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs
19. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
20. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia
21. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
22. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits
23. Triglyceride metabolism in heterozygote of Watanabe heritable hyperlipidemic rabbit
24. Regulation of low density lipoprotein receptor activity in freshly isolated human lymphocytes
25. Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin
26. Coordinate changes in the low density lipoprotein receptor activity of liver and mononuclear cells in the rabbit
27. Standardization of a flow cytometric method for measurement of low-density lipoprotein receptor activity on blood mononuclear cells
28. Comparison of low density lipoprotein uptake by different human lymphocyte subsets: A new method using double-fluorescence staining
29. Flow cytometry with a monoclonal antibody to the low density lipoprotein receptor compared to gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia
30. Flow cytometric assessment of LDL receptor activity in peripheral blood mononuclear cells compared to gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia
31. 66-Gly mutations in the LDL receptor gene: Common causes of familial hypercholesterolemia in Denmark
32. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
33. Assessment of functional low-density-lipoprotein receptors on lymphocytes by a simplified method using culture medium with lipoprotein-free fetal calf serum and pravastatin
34. Lovastatin increases surface low density lipoprotein receptor expression by retarding the receptor internalization rate in proliferating lymphocytes
35. Inhibition of cholesterol synthesis by mevinolin stimulates low density lipoprotein receptor activity in human monocyte-derived macrophages
36. Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins
37. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia
38. Normalization of LDL receptor function by lymphocytes of patients with heterozygous familial hypercholesterolemia after treatment with plasma cholesterol lowering agents
39. Low density lipoprotein receptor mutations in South African homozygous familial hypercholesterolemic patients
40. The effect of pravastatin in relation to low density lipoprotein receptor activity
41. Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblasts
42. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia
43. Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia
44. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells
45. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase
46. Lipid balance in HepG2 cells: Active synthesis and impaired mobilization
47. Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats
48. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
49. Binding of fluvastatin to blood cells and plasma proteins
50. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
51. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors
52. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens
53. Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia
54. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia
55. Low density lipoprotein receptor activity in freshly isolated human blood monocytes and lymphocytes
56. Augmentation of LDL receptor activities on lymphocytes by interleukin-2 and anti-CD3 antibody: A flow cytometric analysis